ReviewInflammopharmacology2026
Targeting PKC/NF-κB/NLRP3-driven NcRNA neuroinflammatory crosstalk by condensed tannins in global cerebral ischemia.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PKC-NF-κB-NLRP3 inflammasome axis and its non-coding RNA (ncRNA) regulatory network triggers robust innate immune activation and neuroinflammation, culminating in neuronal apoptosis and death during Global cerebral ischemia (GCI). The present mechanistic overview illustrates how condensed and hydrolysable tannins, along with related polyphenols, modulate such regulatory network to confer neuroprotection. Ischemia-associated danger signals activate Toll-like receptor-2 (TLR2) through di/tri-acylated lipopolysaccharides, engaging MyD88 and TRAF6 to stimulate protein kinase C (PKC). PKC activation promotes nuclear factor-κB (NF-κB) signaling, leading to interleukin-1β (IL-1β) production and priming of the NLRP3 inflammasome. Subsequent caspase-1 activation drives neuroinflammation and neuronal apoptosis, ultimately resulting in neuronal death. Compounds such as tannic acid, punicalagin, corilagin, pedunculagin, chebulagic acid, chebulinic acid, castalagin, and epigallocatechin gallate (EGCG) suppress NF-κB/IL-1β signaling, while tellimagrandin II, procyanidin C1/B2, paeoniflorin gallate, rosmarinic acid, and savinin directly inhibit NLRP3 activation. Additional phytochemicals, including baicalin and carnosic acid, attenuate upstream PKC signaling. Crucially, these effects are fine-tuned by ncRNAs: miR-146a and miR-155/lncRNA TUG1 regulate NF-κB activity, miR-124 and miR-223 constrain PKC and NLRP3 signaling, and lncRNA NEAT1 modulates caspase-1 activation. Collectively, the integrated suppression of PKC/NF-κB/NLRP3-ncRNA neuroinflammatory signaling by tannins limits inflammasome activation, reduces neuronal apoptosis, and mitigates ischemia-induced neuronal loss. This framework underscores tannins as promising multi-target neuroprotective agents for GCI.
Indexed as
Identifiers
41615569What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.